Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

3 hours ago 3

Jonathan Ponciano, The Motley Fool

Sat, March 21, 2026 astatine 5:18 PM CDT 4 min read

Kynam Capital Management disclosed successful a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $8.18 cardinal commercialized based connected quarterly mean pricing.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Kynam Capital Management sold 469,041 shares of Syndax Pharmaceuticals during the 4th fourth of 2025. The estimated worth of the shares sold was $8.18 million, calculated utilizing the mean closing terms for the quarter. The quarter-end worth of the fund’s Syndax presumption accrued by $38.07 million, a fig that captures some trading and stock terms movements.

Kynam Capital Management’s Syndax presumption was reduced, present accounting for 10.81% of reportable 13F assets nether absorption pursuing the sale.
Top holdings aft the filing:
- NASDAQ:COGT: $218.99 cardinal (14.3% of AUM)
- NASDAQ:VERA: $173.85 cardinal (11.3% of AUM)
- NASDAQ:SNDX: $169.15 cardinal (11.0% of AUM)
- NASDAQ:CLDX: $161.42 cardinal (10.5% of AUM)
- NASDAQ:PCVX: $134.84 cardinal (8.8% of AUM)
As of Friday, shares of Syndax Pharmaceuticals were priced astatine $24.23, up 72% implicit the past twelvemonth and good outperforming the S&P 500’s astir 15% summation successful the aforesaid period.

Metric

Value

Price (as of Friday)	$24.23
Market capitalization	$2.1 billion
Revenue (TTM)	$172.4 million
Net income (TTM)	($285.4 million)

Syndax Pharmaceuticals develops oncology therapies, including SNDX-5613 for acute myeloid leukemia and axatilimab for chronic graft versus big disease, with further pipeline assets specified arsenic Entinostat.
The steadfast operates a clinical-stage biopharmaceutical model, generating gross chiefly done probe collaborations, licensing agreements, and milestone payments.
It targets healthcare providers, probe institutions, and pharmaceutical partners focused connected innovative crab treatments and uncommon illness therapies.

Syndax Pharmaceuticals, Inc. is simply a clinical-stage biotechnology institution specializing successful the improvement of caller crab therapies. The institution leverages a focused pipeline strategy aimed astatine high-need oncology indications, supported by strategical collaborations and licensing agreements. Its accent connected targeted therapies and partnerships positions it to code unmet aesculapian needs successful hematologic malignancies and immune-related disorders.

It’s not astonishing that a money would marque a transaction similar this, cutting immoderate shares but holding onto a still-substantial stake. Syndax generated astir $172 cardinal successful full gross past year, driven by increasing uptake of its precocious launched therapies, including astir $124.8 cardinal from Revuforj and a meaningful publication from its Niktimvo collaboration. That benignant of commercialized traction is uncommon for companies astatine this stage, and it helps explicate wherefore the banal has surged much than 70% implicit the past year.

At the aforesaid time, the concern is inactive burning cash, with a full-year nett nonaccomplishment of astir $285 cardinal and elevated operating expenses tied to R&D and commercialization. That hostility betwixt maturation and profitability is precisely wherever progressive managers thin to rebalance alternatively than afloat exit.

Plus, wrong a portfolio heavy concentrated successful biotech names similar Cogent and Vera, this looks similar a measured accommodation alternatively than a displacement successful thesis. The presumption inactive accounts for much than 10% of assets, aft all, signaling continued conviction.

Read Entire Article